B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2017’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia

The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects

The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Aduro BioTech Inc

BioInvent International AB

Boehringer Ingelheim GmbH

Celgene Corp

Cell Source Inc

Cellectis SA

Dynavax Technologies Corp

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

iDD biotech SAS

Immunomedics Inc

Johnson & Johnson

Juno Therapeutics Inc

Lymphocyte Activation Technologies SA

Mabion SA

MedImmune LLC

MEI Pharma Inc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Novartis AG

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc

TheraMAB LLC

Unum Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

B-Cell Chronic Lymphocytic Leukemia - Overview 8

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 27

AB Science SA 27

Aduro BioTech Inc 27

BioInvent International AB 28

Boehringer Ingelheim GmbH 28

Celgene Corp 29

Cell Source Inc 29

Cellectis SA 30

Dynavax Technologies Corp 30

Elsalys Biotech SAS 31

F. Hoffmann-La Roche Ltd 31

iDD biotech SAS 32

Immunomedics Inc 32

Johnson & Johnson 33

Juno Therapeutics Inc 33

Lymphocyte Activation Technologies SA 34

Mabion SA 34

MedImmune LLC 35

MEI Pharma Inc 35

Millennium Pharmaceuticals Inc 36

Molecular Templates Inc 36

Novartis AG 37

Noxxon Pharma AG 37

Ono Pharmaceutical Co Ltd 38

Portola Pharmaceuticals Inc 38

Regeneron Pharmaceuticals Inc 39

Sunesis Pharmaceuticals Inc 39

TheraMAB LLC 40

Unum Therapeutics Inc 40

B-Cell Chronic Lymphocytic Leukemia - Drug Profiles 41

202-b - Drug Profile 41

2X-121 - Drug Profile 43

AB-8779 - Drug Profile 45

alemtuzumab biosimilar - Drug Profile 46

alisertib - Drug Profile 47

BI-1206 - Drug Profile 53

BI-836826 - Drug Profile 55

BION-1301 - Drug Profile 57

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 59

Cellular Immunotherapy for Hematological Malignancies - Drug Profile 60

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 61

Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 63

Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 65

Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 67

Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 68

Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 69

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 70

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 71

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 72

cerdulatinib - Drug Profile 73

DTRMWXHS-12 - Drug Profile 77

durvalumab - Drug Profile 78

duvortuxizumab - Drug Profile 95

ELB-021 - Drug Profile 97

IDD-001 - Drug Profile 98

IDD-002 - Drug Profile 99

lenalidomide - Drug Profile 100

ME-401 - Drug Profile 117

mRNA ACTR + rituximab - Drug Profile 119

MT-3724 - Drug Profile 121

olaptesed pegol - Drug Profile 124

REGN-1979 - Drug Profile 129

rituximab biosimilar - Drug Profile 130

SD-101 - Drug Profile 132

SNS-062 - Drug Profile 137

TAB-08 - Drug Profile 140

tirabrutinib - Drug Profile 143

tisagenlecleucel-T - Drug Profile 146

tocilizumab - Drug Profile 154

UCART-22 - Drug Profile 164

UCARTCS-1 - Drug Profile 165

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 166

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 168

B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 169

Featured News & Press Releases 169

Appendix 171

Methodology 171

Coverage 171

Secondary Research 171

Primary Research 171

Expert Panel Validation 171

Contact Us 171

Disclaimer 172

List of Tables

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by AB Science SA, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Aduro BioTech Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioInvent International AB, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Boehringer Ingelheim GmbH, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Celgene Corp, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Cell Source Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Cellectis SA, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Dynavax Technologies Corp, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Elsalys Biotech SAS, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by iDD biotech SAS, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Immunomedics Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Johnson & Johnson, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Juno Therapeutics Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Lymphocyte Activation Technologies SA, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Mabion SA, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by MedImmune LLC, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by MEI Pharma Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Molecular Templates Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Novartis AG, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Noxxon Pharma AG, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Portola Pharmaceuticals Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Sunesis Pharmaceuticals Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by TheraMAB LLC, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Unum Therapeutics Inc, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, H2 2017

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, H2 2017 (Contd..1), H2 2017

B-Cell Chronic Lymphocytic Leukemia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports